- Home
- DSU vs TBPH Comparison
DSU vs TBPH Comparison
Compare DSU & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSU
- TBPH
- Stock Information
- Founded
- DSU 1998
- TBPH 2013
- Country
- DSU United States
- TBPH United States
- Employees
- DSU N/A
- TBPH N/A
- Industry
- DSU Finance Companies
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- DSU Finance
- TBPH Health Care
- Exchange
- DSU Nasdaq
- TBPH Nasdaq
- Market Cap
- DSU 519.1M
- TBPH 464.5M
- IPO Year
- DSU N/A
- TBPH N/A
- Fundamental
- Price
- DSU $10.41
- TBPH $9.90
- Analyst Decision
- DSU
- TBPH Buy
- Analyst Count
- DSU 0
- TBPH 3
- Target Price
- DSU N/A
- TBPH $11.33
- AVG Volume (30 Days)
- DSU 148.2K
- TBPH 241.0K
- Earning Date
- DSU 01-01-0001
- TBPH 05-08-2025
- Dividend Yield
- DSU 10.06%
- TBPH N/A
- EPS Growth
- DSU N/A
- TBPH N/A
- EPS
- DSU N/A
- TBPH N/A
- Revenue
- DSU N/A
- TBPH $64,381,000.00
- Revenue This Year
- DSU N/A
- TBPH $51.09
- Revenue Next Year
- DSU N/A
- TBPH N/A
- P/E Ratio
- DSU N/A
- TBPH N/A
- Revenue Growth
- DSU N/A
- TBPH 12.12
- 52 Week Low
- DSU $9.22
- TBPH $7.44
- 52 Week High
- DSU $11.40
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- DSU 60.75
- TBPH 58.86
- Support Level
- DSU $10.26
- TBPH $9.90
- Resistance Level
- DSU $10.40
- TBPH $10.55
- Average True Range (ATR)
- DSU 0.09
- TBPH 0.36
- MACD
- DSU 0.05
- TBPH 0.07
- Stochastic Oscillator
- DSU 96.72
- TBPH 67.98
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).